These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27579329)

  • 1. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
    Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
    J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.
    Marszal E; Fowler E
    J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.
    Rosenberg AS; Verthelyi D; Cherney BW
    J Pharm Sci; 2012 Oct; 101(10):3560-7. PubMed ID: 22736548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.
    Sauna ZE; Lagassé D; Pedras-Vasconcelos J; Golding B; Rosenberg AS
    Trends Biotechnol; 2018 Oct; 36(10):1068-1084. PubMed ID: 29908714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.
    Johnson R; Jiskoot W
    J Pharm Sci; 2012 Oct; 101(10):3586-92. PubMed ID: 22736238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein particles: what we know and what we do not know.
    Ripple DC; Dimitrova MN
    J Pharm Sci; 2012 Oct; 101(10):3568-79. PubMed ID: 22736521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico methods for design of biological therapeutics.
    Roy A; Nair S; Sen N; Soni N; Madhusudhan MS
    Methods; 2017 Dec; 131():33-65. PubMed ID: 28958951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of therapeutic proteins: the use of animal models.
    Brinks V; Jiskoot W; Schellekens H
    Pharm Res; 2011 Oct; 28(10):2379-85. PubMed ID: 21744171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.
    Wang YM; Jawa V; Ma M
    Bioanalysis; 2014 Jan; 6(1):79-87. PubMed ID: 24341496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
    Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
    J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.
    Turner MR; Balu-Iyer SV
    J Pharm Sci; 2018 May; 107(5):1247-1260. PubMed ID: 29336981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
    Vugmeyster Y; Harrold J; Xu X
    AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
    Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
    Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.
    Kuriakose A; Chirmule N; Nair P
    J Immunol Res; 2016; 2016():1298473. PubMed ID: 27437405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.